Focuses on developing and commercializing therapies for rare and orphan diseases, utilizing its proprietary drug delivery platforms.
Conduit Pharmaceuticals Inc., based in San Diego, California, is a clinical-stage specialty biopharmaceutical company dedicated to addressing unmet medical needs in autoimmune diseases and idiopathic male infertility. The company focuses on developing innovative pharmaceutical products that aim to improve patient outcomes in these challenging therapeutic areas.
Conduit Pharmaceuticals robust pipeline includes promising candidates such as AZD1656, which has completed Phase I trials targeting conditions like type 2 diabetes, renal transplant complications, Hashimoto's thyroiditis, Grave's disease, uveitis, and preterm labor. Additionally, AZD5904, another key candidate, has also completed Phase I clinical trials specifically designed for the treatment of idiopathic male infertility. These advancements underscore Conduit Pharmaceuticals' commitment to advancing novel therapies through rigorous clinical research and development.
Founded in 2019, Conduit Pharmaceuticals operates as a subsidiary of Corvus Capital Limited, leveraging strategic partnerships and a focused approach to drive forward its mission of addressing critical medical needs with cutting-edge pharmaceutical innovation. The company continues to expand its footprint in the biopharmaceutical industry, aiming to deliver impactful therapies that make a difference in patients' lives worldwide.